Drug Name: Q-cells
Company: Q Therapeutics
Location: US-Utah
Website: http://www.qthera.com/
Drug Type: Stem Cell Therapy
Conditions: ALS, transverse myelitis, multiple scleorsis, spinal cord injury
Mechanism Type: Neuroprotection
Mechanism: Q-cells are purified human glial-restricted progenitors derived from human fetal neural tissue. In rats overexpressing mutant superoxide dismutase (SOD1), transplanted glial-restricted precursors prolong lifespan, reduce microgliosis, improve motor neuron survival and attenuate decline in motor and respiratory function. In SOD1 mice, transplantation did not attenuate motor neuron death or improve survival, however, the glial-restricted progenitors survived and differentiated into astrocytes in the spinal cord.
U.S. Status for ALS: Phase I/IIa

[1] Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells) Into Subjects With Amyotrophic Lateral Sclerosis (ALS). ClinicalTrials.gov, 18 Jun 2015. Accessed 11 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT02478450.
[2] Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Lepore, AC et al. Nat Neurosci. 2008 Nov;11(11):1294-301.
[3] Human glial-restricted progenitor transplantation into cervical spinal cord of the SOD1 mouse model of ALS. Lepore, AC et al. PLoS One. 2011;6(10):e25968.

Last updated June 21st, 2017

Share this: